https://na.eventscloud.com/website/91375/
This January in San Francisco, join a panel of 3 leading experts for a 90-minute program on the evolving landscape of pancreatic adenocarcinoma (PDAC) treatment. This dynamic discussion will focus on the remarkable evolution of renin-angiotensin system (RAS) inhibitors in PDAC, tracing the journey from when RAS was considered undruggable to the latest data on novel mechanisms and therapies targeting RAS in its active state. Don't miss this opportunity to gain insights into the future of PDAC management and engage with the experts directly during a dedicated question-and-answer session.
No hay comentarios:
Publicar un comentario